TRIGR Therapeutics and Elpiscience Biopharmaceuticals Announce $117 Million Exclusive China Licensing Transaction for TR009, a Phase 1B Dual Angiogenic Bispecific Antibody Targeting DLL4/VEGF
- Transaction to immediately accelerate clinical development of TR009 in Greater China and combine with Elpiscience s deep pipeline of next generation immunotherapies
- TRIGR and Elpiscience intend to harmonize future clinical development globally across multiple DLL4 overexpressed solid tumors
- TRIGR to receive a $7 million upfront cash payment, $110 million in potential milestones, and royalties
News provided by
Share this article
Share this article
IRVINE, Calif. and SHANGHAI, Jan. 20, 2021 /PRNewswire/ TRIGR Therapeutics, Inc. ( TRIGR ), a US based clinical stage biopharmaceutical company focused on the development of multi-targeted angiogenic and immunomodulatory bispecific antibodies for oncology and certain ischemic indications and Elpiscience Biopharmaceuticals, a leading Chin